Among the molecular alterations identified in this population and in the search for new targetable oncogenic drivers following the success of tyrosine kinase inhibitors (TKIs) against EGFR, a chromosomal translocation involving the ROS1 gene has been identified in the oncogenesis of lung cancer [3]. This evidence concerns the gene ROS1 and lung cancer.